KalVista Pharmaceuticals, Inc. Stock News

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the Company will participate in a fireside chat at each of the following investor conferences: TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 1:10 p.m. ET in Boston, MA Leerink Partners 2025 Global Healthcare Conference on Monday, March 10, 2025,...

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that six abstracts have been accepted for presentation at the American Academy of Allergy, Asthma & Immunology (AAAAI) / World Allergy Organization (WAO) 2025 Joint Congress taking place in San Diego, CA from February 28–March 3, 2025. The following poster presentations will tak...

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the presentation of novel data related to long-term prophylaxis and sebetralstat at the Western Society of Allergy, Asthma & Immunology (WSAAI) 2025 Annual Meeting taking place in Waimea, HI from February 9-13, 2025. Raffi Tachdjian, MD, MPH, Associate Clinical Professor of Med...

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista's board of directors granted fifty-two newly-hired employees inducement options to purchase an aggregate of 261,000 shares of KalVista common stock on February 3, 2025 as inducements material to each employee entering into employment ...

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has granted sebetralstat Orphan Drug Designation. The Company has also submitted a New Drug Application (NDA) for sebetralstat to the Agency. If approved, sebetralstat, a novel, investigational oral plasma kallikrein in...

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) today announced that the compensation committee of KalVista's board of directors granted nine newly-hired employees inducement options to purchase an aggregate of 61,000 shares of KalVista common stock on January 2, 2025 as inducements material to each employee entering into employment with Kal...

NDA submission of sebetralstat was accepted for review by the FDA as an on-demand treatment option for HAE patients, with a PDUFA review date of June 17th of 2025. If sebetralstat is approved by the FDA, it would be the first and only on-demand oral treatment for HAE patients ages 12 and older. The global Hereditary Angioedema treatment market size is projected to reach $17.31 billion by the en...

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Jeb Ledell has joined the Company as Chief Operating Officer (COO). Mr. Ledell is an accomplished public company COO with a track record of driving operational excellence and strategic growth within the biotechnology industry. “I am pleased to welcome Jeb to KalVista at th...